Open AccessPhase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements
Author(s) -
D. Neil Hayes,
Amy Lucas,
Tawee Tanvetya,
Monika K. Krzyzanowska,
Christine H. Chung,
Barbara A. Murphy,
Jill Gilbert,
Ranee Mehra,
Dominic T. Moore,
Arif Sheikh,
Janelle M. Hoskins,
Michele C. Hayward,
Na Zhao,
Wendi O'Connor,
Karen E. Weck,
Roger B. Cohen,
Ezra E.W. Cohen
Publication year - 2012
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/6k9v-5662
Subject(s) - thyroid carcinoma , refractory (planetary science) , follicular phase , medicine , selumetinib , iodine , oncology , endocrinology , thyroid , cancer research , chemistry , biology , cancer , colorectal cancer , organic chemistry , astrobiology , kras